secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioNexus Gene Lab Corp (BGLC)
CIK:        0001737523
Form:       8-K
Filed at:   2026-10-07T13:00:24+00:00
Accession:  0001477932-26-006075
Event type: m_and_a
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

BioNexus signs CogniAI healthcare licence with RYET, paying 560,000 shares (~16% stake)
--------------------------------------------------------------------------------

- BGLC to issue 410,000 shares for stated US$3.5M licence consideration plus 150,000 shares for 500,000 RYET ordinary shares; 560,000 total, ~16.0% of post-issuance shares.
- Ten-year exclusive Malaysian healthcare licence with two five-year renewals; RYET gets 10% royalty on technology receipts collected, with no minimum royalty or annual platform fee.
- Closing pending: RYET must deliver technology by December 4, 2026; acceptance testing, due diligence and approvals required, with termination possible if no closing by March 31, 2027.
- Malaysia raised public healthcare digitalization allocation to RM1 billion covering 150 hospitals and 2,000+ clinics; MOH targets electronic medical records nationwide by 2029.
- BGLC has not been awarded any government contract, and public-sector work depends on government procurement; RYET reported ~US$1.73M contracted CogniAI activity in June 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737523/000147793226006075/0001477932-26-006075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737523/000147793226006075/bglc_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-26-006075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer